The conference consists of four areas, one being the Aescap Investment Room chaired by Hakan Goker. The Investment Room is a highly recommended investment seminar; already by many considered as one of the best in Europe.

How to apply for an investment pitch, see below.

Presenting companies 2011:

The Investment pitch includes following marketing opportunities:

• Choose between:
• 15 minutes presentation in Aescap Venture Investment Room or
• 10 minutes presentation and 5 minutes Q/A
• Company name and logo on the conference website with hyperlink
• Short company introduction on the conference website
• Presentation about the Investment pitch in the conference programme
• The opportunity to pre-book two one-to-one meetings at the conference
• Receive invitations to a drink reception (kick-off) the evening before the event

Investment pitch fee: £1.000 (Excl VAT)

If you want to apply for an Investment pitch or if you need additional information, then please contact:

Mattias Johansson
Ezenze Ltd
Email: mattias.johansson@ezenze.com
Office: +44 (0)20 7795 8132 
Fax: +44 (0)20 7795 4777

Example of investors and pharmaceuticals that have attended on previous events:

Abingworth Management
Abbott Laboratories
Advent Ventures
Aescap Ventures
AGF Private Equity
Alliance Venture
Alta Partners
Amgen Ventures
Apax Partners
Apposite Capital
Ascenion GmbH
Astellas Pharma
Atlas Venture LLP
AztraZeneca
Avlar Bioventures Ltd
Bankinvest
Bayer Healthcare
Bellevue Asset Management
Biofund
BioMedinvestor AG
Boehringer Ingelheim
Bohus Capital
Breslin Biotech AG
Bristol-Myers Squibb
Burdaras hf
Cambridge Enterprise Seed Funds
Capman
CDC Innovation
Cinven
Credit Agricoure
Danske Markets
Deutsche Venture Capital
DnBNor
EarlyBird
ECI Partners LLP
Edmond de Rothschild Investment Partners
Eli Lilly & CO
EMBL Venture Capital Partners
Entrepreneurs Fund LLP
EPIC Investment Partners
Eisai Europe
Esperante Ventures
European Investment Fund
Exponent Private Equity LLP
GE Healthcare Financial Services
Genzyme Ventures
Gilde Investment Management
GlaxoSmithKline
Global Life Sciences Ventures
Goldman Sachs
Graphite Capital
HBM Partners AG
Healthcap
Imperial Innovations
Index Ventures
Innovationskapital
International Bioscience Managers
Inventages Venture Capital
Investor Growth Capital
Javelin Ventures
Jeffries International
Johnson & Johnson
Karolinska Investment Fund
LEO Pharma
Life Sciences Partners
Linkmed
London Business Angels
London Technology Fund
LRM
Medimmune Ventures
Mercia Technology Seed Fund
Merck Serono Ventures
Merck Sharp & Dohme
Merlin Biosciences
Mitsui & Co Europe plc
MVM Life Science partners LLP
N M Rothschild & Sons Limited
NeoMed
NGN Capital
Nomura Code
Nomura/Novartis Phase 4 Ventures
Nordic Biotech
Northern  Venture Managers
Novaquest
Novartis Venture Fund
Novo A/S
Novo Seeds
Novo Venture
NovoSeeds
Omega Fund
Oxford Capital Partners
Paul Capital Partners
Pfizer Limited
Pfizer Venture Investments
Phase4 Ventures
Rainbow Seed Fund
Roche Venture Fund
Rosetta Capital Ltd
Sarsia Innovation
Sarsia Seed Fund
Scandinavian life science venture
Schroder Venture Life Science
Scottish Equity Partners
Seed Capital
Seroba Kernel
Shire Pharmaceutical
Sofinnova Partners
Takeda Pharmaceutical
Teva Pharmaceutical
TVM Capital
Vaekstfonden
Versant EuroVentures
Wallder Capital Ltd
Wellcome Trust
Wellington Partners
Wyeth Pharmaceuticals
Versant EuroVentures
Ysios Capital Partners